Viewing data from:

ELURYNG

ANDA

ETHINYL ESTRADIOL; ETONOGESTREL | A210830 | AMNEAL PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: NUVARING(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Eluryng (2023)

Total Spending

$784K

Total Claims

3,576

Beneficiaries

1,245

Avg Cost/Unit

$99.84

Spending Trend

$5K(2019)→$456K(2020)→$624K(2021)→$710K(2022)→$784K(2023)

YoY Change:-3.8%

5yr CAGR:-7.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Mar 23, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.015MG/24HR;0.12MG/24HR

0 patents0 exclusivities▴

RING;VAGINAL | Approved: Dec 11, 2019

No patent or exclusivity listings for this strength.